evaxion-biotech-logo1big.png
Evaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership Award
October 14, 2021 07:30 ET | Evaxion Biotech
Recognizes achievements in AI-enabled drug discoveryHighlights how Evaxion’s platforms help to design novel immunotherapies efficiently COPENHAGEN, Denmark, Oct. 14, 2021 (GLOBE NEWSWIRE) --...
evaxion-biotech-logo1big.png
Evaxion Biotech to Present Work on AI-Immunology Core Technology at Immuno UK 2021
October 12, 2021 16:05 ET | Evaxion Biotech
COPENHAGEN, Denmark, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
evaxion-biotech-logo1big.png
Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer
September 21, 2021 08:34 ET | Evaxion Biotech
Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21,...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update
August 12, 2021 06:30 ET | Evaxion Biotech
Data reported in early July from EVX-01 clinical program showed a robust anti-tumor effect in combination with anti-PD-1 treatment for patients with metastatic melanoma, supporting advancement into a...
evaxion-biotech-logo1big.png
Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02
July 08, 2021 06:00 ET | Evaxion Biotech
New clinical data demonstrates antitumor effect of EVX-01 in combination with anti-PD1 treatmentObjective Response Rate (ORR) of 67% with EVX-01 + anti-PD1 treatment in nine metastatic melanoma...
evaxion-biotech-logo1big.png
Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8
July 07, 2021 17:01 ET | Evaxion Biotech
COPENHAGEN, Denmark, July 07, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
evaxion-biotech-logo1big.png
Evaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic Programming
June 25, 2021 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, June 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
evaxion-biotech-logo1big.png
Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine
June 03, 2021 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, June 03, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotech company developing AI-driven immunotherapies and vaccines to improve the lives of...
evaxion-biotech-logo1big.png
Evaxion Biotech Appoints Lars Holtug to the Board of Directors
May 26, 2021 08:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update
May 13, 2021 07:30 ET | Evaxion Biotech
Raised net proceeds of $27.9 million in U.S. initial public offering in February 2021Lead programs EVX-01 and EVX-02 on track for Phase 1/2a data readouts late in Q2Product candidates EVX-03 and...